References
- Ahn KS, Sethi G, and Agarwal BB (2008). Reversal of chemoresistance and enhancement of apoptosis by statins through down-regulation of the NF-kappaB pathway. Biochem. Pharmacol. 75, 907–913.
- Damrot J, Nubel T, Epe B, Roos WP, Kaina B, and Fritz G (2006). Lovastatin protects human endothelial cells from the genotoxic and cytotoxic effects of the anticancer drugs doxorubicin and etoposide. Br. J. Pharmacol. 149, 988–997.
- Feleszko W, Mlynarczuk I, Balkowiec-Iskra EZ, Czajka A, Switaj T, Stoklosa T, and et al (2000). Lovastatin potentiates antitumor activity and attenuates cardiotoxicity of doxorubicin in three tumor models in mice. Clin. Cancer Res. 6, 2044–2052.
- Ferguson L, and Denny WA (2007). Genotoxicity of noncovalent DNA interactions: DNA intercalators. Mutat. Res. 623 (1–2), 4–14.
- Gnad R, Aktories K, Kaina B, and Fritz G (2000). Inhibition of protein isoprenylation impairs Rho-regulated early cellular response to genotoxic stress. Mol. Pharmacol. 58, 1389–1397.
- Riganti C, Orecchia S, Pescarmona G, Betta PG, Ghigo D, and Bosia A (2006). Statins revert doxorubicin resistance via nitric oxide in malignant mesothelioma. Int. J. Cancer 119, 17–27.
- Snyder RD, and Brown JE (2002). Evidence for and role of the dimethylamino group in tamoxifen DNA intercalation in intact Chinese hamster V79 cells. Drug Chem. Toxicol. 25, 473–479.
- Snyder RD (2000). Use of catalytic topoisomerase inhibitors to probe mechanisms of chemical-induced clastogenicity in Chinese hamster V79 cells. Environ. Mol. Mutagen. 35, 13–21.
- Snyder RD (2003). Evidence from studies with intact mammalian cells that merbarone and bis(dioxopiperazine)s are topoisomerase II poisons. Drug Chem. Toxicol. 26, 15–22.
- Snyder RD (2007). Assessment of atypical DNA intercalating agents in biological and in silico systems. Mut. Res. 623, 72–82.
- Snyder RD, and Arnone MR (2002). Putative identification of functional interactions between DNA intercalating agents and topoisomerase II using the V79 in vitro micronucleus assay. Mutat. Res 503, 21–35.
- Snyder RD, Ewing DE, and Hendry LB (2004). Evaluation of DNA intercalation potential of pharmaceuticals and other chemicals by cell-based and 3-dimensional computational approaches. Environ. Mol. Mutagen. 44, 163–173.
- Snyder RD, Ewing D, and Hendry LB (2006). DNA intercalative potential of marketed drugs testing positive in in vitro cytogenetics assays. Mutat. Res 609, 47–59.
- Snyder RD, and Gillies PJ (2002). Evaluation of the clastogenicity, DNA intercalating, and topoisoemerase II interactive properties of bioflavonoids in Chinese hamster V79 cells. Environ. Mol. Mutagen. 40, 266–276.
- Snyder RD, and Green JW (2001). A review of the genotoxicity of marketed pharmaceuticals. Mutat. Res. 488, 151–169.
- Snyder RD, McNulty J, Zairov G, Ewing DE, and Hendry L B (2005). The influence of N-dialkyl and other cationic substituents on DNA intercalation and genotoxicity. Mutat. Res. 578, 88–99.
- Snyder RD, and Strekowski L (1999). Enhancement of bleomycin-induced micronucleus formation in V79 cells as a rapid and sensitive screen for noncovalent DNA binding compounds. Mutat. Res. 444, 181–192.
- Strekowski L (1992). Molecular basis for the enhancement or inhibition of bleomycin-mediated degradation of DNA by DNA-binding compounds. Adv. Detail. React. Mech. 2, 61–109.
- von Bardeleben R, Dunkern T, Kaina B, and Fritz G (2002). The HMG-CoA reductase inhibitor lovastatin protects cells from the antineoplastic drugs doxorubicin and etoposide. Int. J. Mol. Med. 10, 473–479.